Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Metabolic Effects of Melatonin Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03204877
Recruitment Status : Completed
First Posted : July 2, 2017
Last Update Posted : March 25, 2020
Sponsor:
Collaborator:
University of Copenhagen
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:
Modern living is associated with an epidemic of type 2 diabetes mellitus (T2DM). Sleep disturbances are strong independent risk factors for incident diabetes. Melatonin has been implicated in regulation of circadian rhythm and sleep, but it is also ascribed anti-oxidative properties and effects on glucose homeostasis. A potential association between melatonin and T2DM has only been addressed in few human physiological studies, but the topic has received renewed interest since genetic-epidemiological studies have pointed to a role for melatonin in the development of the disease. In the current study, the investigators wish to examine whether treatment with synthetic melatonin induces physiological changes that affect the risk of developing type 2 diabetes. Two studies of the physiological effects of melatonin are included in the present protocol. In study A, the investigators will examine the acute effects of Melatonin on insulin secretion and insulin sensitivity using a Botnia clamp and in study B the investigators will examine the potential effects of Melatonin on the incretin response.

Condition or disease Intervention/treatment Phase
Glucose Metabolism Disorders Drug: Melatonin Other: Placebo Phase 1 Phase 2

Detailed Description:

Modern living is associated with an epidemic of type 2 diabetes mellitus (T2DM). Sleep disturbances such as insomnia and frequent awakenings are strong independent risk factors for incident diabetes with a magnitude of effect comparable to a family history of diabetes. Melatonin has been implicated in regulation of circadian rhythm and sleep, but it is also ascribed anti-oxidative properties and effects on glucose homeostasis. In pancreatic islets melatonin have dual effects depending on which signaling pathway is activated by receptor binding, thus both inhibitory and stimulatory effects on insulin secretion have been reported. The effect of melatonin on the secretion of gut hormones such as glucagon-like peptide 1 (GLP-1) and influence of melatonin on beta cell sensitivity to gut hormones is largely unknown, but the presence of the melatonin receptor in the gut suggests that it may have a role. A potential association between melatonin and T2DM has only been addressed in few human physiological studies, but the topic has received renewed interest since genetic-epidemiological studies have pointed to a role for melatonin in the development of the disease. Genetic mutations in the melatonin receptor which is predicted to change the physiological effects of melatonin have been found to increase the risk for T2DM. Additionally, low endogenous melatonin production has been linked to T2DM risk.

The aim of the present study is to examine whether treatment with synthetic melatonin induces physiological changes that affect the risk of developing type 2 diabetes.

Two studies of the physiological effects of melatonin are included in the present protocol:

Study A:

In order to study the acute effects of melatonin administration in healthy men, the investigators aim for assessing whether:

  • Melatonin affects the substrate turn-over as evaluated by indirect calorimetry
  • Melatonin has influence on the ability to secrete insulin as assessed by intravenous glucose tolerance test
  • Melatonin affects the physiological effects of insulin as assessed by use of the hyperinsulinemic euglycemic clamp
  • Genetic mutations in the melatonin receptor gene affect the treatment response to melatonin

Study B:

The investigators aim for examining if melatonin given to healthy men affects the secretion of the glucose-lowering gut hormone glucagon-like peptide 1 (GLP-1) and/or affect the glucose-lowering effects of GLP-1. Specifically, the aim is to assess whether:

  • Melatonin affects the glucose excursions and insulin secretion during an oral glucose tolerance test
  • Melatonin affects the secretion of GLP-1 during an oral glucose tolerance test
  • Melatonin affects the incretin response as assessed by an isoglycemic glucose infusion

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Acute Metabolic Effects of Melatonin Treatment
Actual Study Start Date : August 22, 2017
Actual Primary Completion Date : February 27, 2019
Actual Study Completion Date : February 1, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Melatonin

Arm Intervention/treatment
Active Comparator: Melatonin
Four capsules of Melatonin 10 mg is administered orally every hours for four hours during the study day.
Drug: Melatonin
Oral capsules

Placebo Comparator: Placebo
Four capsules of placebo is administered orally every hours for four hours during the study day.
Other: Placebo
Oral capsules




Primary Outcome Measures :
  1. Insulin sensitivity [ Time Frame: 2 hours (from t= 105 to 225 minutes) ]
    Insulin sensitivity is assessed by a hyperinsulinemic euglycemic clamp, unit: mg/kg/min

  2. Insulin secretion [ Time Frame: 1 hour (from t = 45 to 105 minutes) ]
    Insulin secretion is assessed by an intravenous glucose tolerance test, unit: pmol/L (insulin)

  3. Incretin response [ Time Frame: 4 hours (from t = 0 to 240 minutes) ]
    The incretin response is assessed by the difference in incretin hormones between an oral glucose tolerance test and an isoglycemic intravenous glucose infusion, unit: pmol/L (GIP, GLP-1)


Secondary Outcome Measures :
  1. Inflammatory markers [ Time Frame: Baseline t = -60 minutes and at t = 45 minutes ]
    Assessed by blood samples, unit: pg/mL

  2. Substrate oxidation [ Time Frame: From t=15 minutes to 45 minutes and from t=195 minutes to 225 minutes ]
    Substrate oxidation is assessed by indirect calorimetry. Glucose oxidation: unit: mg/kg/min; protein oxidation: unit: mg/kg/min; lipid oxidation: unit: mg/kg/min

  3. Hormones [ Time Frame: Baseline t = -60 minutes and at t = 45 minutes ]
    Hormones are assessed by blood samples. Units: C-peptide: pmol/L; Cortisol: ng/mL; Adiponectin: mg/L; IGF-I (ng/ml)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male sex
  • Age 20-40 years
  • BMI between 22-30 kg/m2
  • Written consent prior to study participation

Exclusion Criteria:

  • Diabetes or impaired glucose tolerance (fasting p-glucose ≥ 6.1mmol/L)
  • Daily use of a prescription drug
  • Shift work within the last year
  • Travel across >2 time zones in the past three months
  • Use of melatonin on a regular basis within the last year
  • Severe illness
  • High performance athletes
  • Daily tobacco smoking
  • Previous diagnosis of a sleep disorder
  • Present or earlier alcohol or drug abuse
  • Unable to give informed consent
  • Allergy towards melatonin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03204877


Locations
Layout table for location information
Denmark
Aarhus University Hospital
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
University of Copenhagen
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT03204877    
Other Study ID Numbers: Mel06062017
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: March 25, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Aarhus:
Melatonin
Insulin sensitivity
Insulin secretion
Incretin response
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Diseases
Glucose Metabolism Disorders
Melatonin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Central Nervous System Depressants